PDT Partners LLC Takes $536,000 Position in Indivior PLC (NASDAQ:INDV)

PDT Partners LLC purchased a new position in Indivior PLC (NASDAQ:INDV - Free Report) in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 54,924 shares of the company's stock, valued at approximately $536,000.

Several other hedge funds have also recently modified their holdings of INDV. Bank of New York Mellon Corp purchased a new stake in Indivior in the second quarter worth approximately $188,000. VELA Investment Management LLC bought a new stake in shares of Indivior in the second quarter worth $235,000. Hsbc Holdings PLC increased its position in Indivior by 624.5% during the second quarter. Hsbc Holdings PLC now owns 74,380 shares of the company's stock valued at $1,165,000 after acquiring an additional 64,114 shares during the last quarter. XTX Topco Ltd bought a new position in Indivior in the second quarter valued at about $249,000. Finally, Marshall Wace LLP boosted its position in Indivior by 493.2% in the second quarter. Marshall Wace LLP now owns 73,732 shares of the company's stock worth $1,189,000 after purchasing an additional 61,302 shares during the last quarter. Hedge funds and other institutional investors own 60.33% of the company's stock.

Analyst Ratings Changes

INDV has been the subject of several recent research reports. Craig Hallum cut their target price on shares of Indivior from $20.00 to $16.00 and set a "buy" rating for the company in a research report on Friday, October 11th. Piper Sandler reaffirmed an "overweight" rating and issued a $16.00 target price (up from $15.00) on shares of Indivior in a report on Friday, October 25th.

Indivior Stock Performance

Indivior stock traded down $0.03 during midday trading on Tuesday, hitting $11.20. The stock had a trading volume of 986,239 shares, compared to its average volume of 532,779. The company has a current ratio of 0.83, a quick ratio of 0.65 and a debt-to-equity ratio of 23.50. Indivior PLC has a 52-week low of $7.33 and a 52-week high of $23.22. The company has a market capitalization of $1.54 billion, a PE ratio of -279.93 and a beta of 0.75. The firm's fifty day moving average is $9.70 and its two-hundred day moving average is $12.20.

Indivior (NASDAQ:INDV - Get Free Report) last released its earnings results on Thursday, October 24th. The company reported $0.54 earnings per share for the quarter, beating analysts' consensus estimates of $0.39 by $0.15. The company had revenue of $307.00 million for the quarter, compared to analysts' expectations of $302.25 million. Indivior had a negative net margin of 0.17% and a negative return on equity of 351.08%. On average, research analysts forecast that Indivior PLC will post 1.66 EPS for the current year.

Indivior Profile

Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose.